LOGIN  |  REGISTER
Assertio

Latest Medical Device Stock News

Tandem Diabetes Care Announces Upcoming Conference Presentations

November 21
Last Trade: 30.74 0.59 1.96

SAN DIEGO / Nov 21, 2024 / Business Wire / Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024 at 8:00am Eastern Time (5:00am Pacific Time), and Citi’s 2024 Global Healthcare Conference on Wednesday, December 4,...Read more


Hyperfine Swoop® Portable MR Brain Imaging System Meets New Standards Recently Issued by CMS-Approved Accrediting Body

November 21
Last Trade: 0.98 0.08 9.33

Intersocietal Accreditation Commission (IAC)’s release of new standards accepting ultra-low-field MRI technology enables accredited facilities to qualify for reimbursement from the US Centers for Medicare & Medicaid Services (CMS). GUILFORD, Conn. / Nov 21, 2024 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic...Read more


Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis

November 21
Last Trade: 0.32 -0.0003 -0.09

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company received three notices of allowance in countries within the European Patent Organization (EPO), including Germany, UK, France, Italy, Spain, and over 30 additional nations within the European Patent Treaty IRVINE, Calif., Nov. 21, 2024...Read more


Nano-X Imaging Announces Third Quarter of 2024 Financial Results and Provides Business Update

November 21
Last Trade: 6.16 0.27 4.58

Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a key component of global strategic growth plan Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET PETACH TIKVA, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) -- November 21, 2024 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging...Read more


Spectral AI Announces DeepView SnapShot® M Moves Forward with Feedback from Brooke Army Medical Center Institute of Surgical Research

November 21
Last Trade: 1.14 0.08 7.55

DALLAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (Spectral AI or the Company), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced its DeepView SnapShot® M device continues to develop based upon preliminary feedback from its usability study with the Brooke Army Medical Center and the U.S. Army...Read more


Zimmer Biomet to Present at Citi's 2024 Global Healthcare Conference

November 21
Last Trade: 108.40 -0.87 -0.80

WARSAW, Ind., Nov. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Citi Global Healthcare Conference on December 5, 2024, with a fireside chat at 8:45 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived...Read more


Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

November 21
Last Trade: 2.98 -3.19 -51.70

[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi) Eight of nine patients had durable control of disease. Six of nine patients had a measurable reduction of tumor volume, one of whom had a confirmed response as defined by RECIST v1.1. Signal of anti-tumor activity was generally more pronounced in patients with lower body weight Perspective...Read more


Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

November 21
Last Trade: 17.09 0.23 1.36

ROOT, Switzerland / Nov 21, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas. Novocure will present the results of its work to design arrays that will allow efficient and stable delivery of TTFields in...Read more


FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

November 21
Last Trade: 17.09 0.23 1.36

New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users ROOT, Switzerland / Nov 21, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio® for the treatment of adult patients with glioblastoma multiforme (GBM). Optune Gio is a wearable, portable device...Read more


Modular Medical Announces Proposed Public Offering

November 21
Last Trade: 1.94 -0.12 -5.83

SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock (or pre-funded warrants to purchase...Read more


Nanalysis Scientific Announces Third Quarter 2024 Results

November 21
Last Trade: 0.37 0.005 1.37

Company Achieved 50% YoY Revenue Growth & Positive EBITDA CALGARY, AB, Nov. 21, 2024 /CNW/ - Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR machines and MRI technology for industrial and research applications announces third quarter results for the period ending on September 30, 2024, achieving 50% year-over-year revenue growth to $10.6 million in Q3. Chief...Read more


Penumbra to Present at the Piper Sandler 36th Annual Healthcare Conference

November 20
Last Trade: 240.49 1.29 0.54

ALAMEDA, Calif., Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. Event:     Piper Sandler 36th Annual Healthcare ConferenceDate:      Wednesday, December 4, 2024Time:      8:00am ET/5:00am PT A webcast of the...Read more


CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

November 20
Last Trade: 14.77 1.25 9.25

MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor...Read more


SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

November 20
Last Trade: 12.29 0.14 1.15

SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. Investors interested in listening to...Read more


Perimeter Medical Imaging AI B-Series OCT with ImgAssist AI 2.0 Demonstrates Super-Superiority Compared to Standard-of-Care in Pivotal Clinical Trial

November 20
Last Trade: 0.62 -0.04 -6.06

Intraoperative margin assessment during BCS using Perimeter B-Series OCT with ImgAssist AI 2.0 enabled surgeons to more effectively address residual cancer at the surgical margin as compared to current standard methods Primary endpoint met with statistically significant reduction in patients with residual cancer during surgery (p-value = 0.0050) B-series super-superiority based on predefined clinical and statistical significance...Read more


Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference

November 20
Last Trade: 6.42 0.22 3.55

REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET. A live and archived webcast of the presentation will be available...Read more


enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

November 20
Last Trade: 3.30 -0.07 -2.08

85% Clinical Meaningful Benefit Responder Rate 7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort 75% Median Reduction in Pain (VAS) 87% Median Ulcer Area Reduction 97% Target Vein Patency Rate Improvement in All Patient Reported Quality-of-Life Indicators Company to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA /...Read more


Medtronic receives FDA clearance for new InPen™ app, paving the way for its Smart MDI system launch with Simplera™ CGM

November 20
Last Trade: 84.74 0.63 0.75

New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. GALWAY, Ireland, Nov. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for...Read more


Stereotaxis: Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

November 20
Last Trade: 2.05 0.02 0.99

ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System. “We are excited to be at the forefront of technology and patient care by...Read more


BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

November 20
Last Trade: 9.84 0.01 0.10

BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic stimulation (Deep TMS™) in patients with peripheral...Read more


Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

November 20
Last Trade: 1.00 -0.001 -0.10

NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has submitted its complete clinical evidence package for its EsoGuard® Esophageal DNA Test in support of a Request for Reconsideration of Local Coverage Determination (LCD) L39256...Read more


Baxter to Present at 7th Annual Evercore HealthCONx Conference

November 19
Last Trade: 32.99 0.36 1.10

DEERFIELD, Ill. / Nov 19, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 9:10 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, June 3,...Read more


Becton Dickinson to Present at the 7th Annual Evercore ISI HealthCONx Conference

November 19
Last Trade: 225.45 3.06 1.38

FRANKLIN LAKES, N.J., Nov. 19, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 10:50 am Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be...Read more


Varex Imaging Announces Financial Results for Fourth Quarter and Fiscal Year 2024

November 19
Last Trade: 16.51 1.09 7.07

SALT LAKE CITY / Nov 19, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the fourth quarter and fiscal year 2024. Q4 FY24 Summary Revenues of $206 million GAAP gross margin 33% | Non-GAAP gross margin* 33% GAAP operating expense $56 million | Non-GAAP operating expense* $53 million GAAP operating margin 5% | Non-GAAP operating margin* 7% GAAP net earnings $(1.22)...Read more


Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

November 19
Last Trade: 3.76 0.03 0.80

MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY. Sight Sciences’ management is scheduled to...Read more


Tactile Medical to Present at the Piper Sandler 36th Annual Healthcare Conference

November 19
Last Trade: 15.94 0.38 2.44

MINNEAPOLIS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from December 3rd – 5th. Management will participate in a...Read more


Hyperfine Announces Ten Abstracts at RSNA, Highlighting the Expanding Utility and Potential of Portable MR Brain Imaging in Diverse Clinical and Research Settings

November 19
Last Trade: 0.98 0.08 9.33

The breadth of data being presented at the premier radiology meeting of 2024 illustrates the increasing relevance of portable, ultra-low-field MR brain imaging. GUILFORD, Conn. / Nov 19, 2024 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that...Read more


Stryker unveils Oculan Lighting Platform to enhance surgical visualization and illumination

November 19
Last Trade: 390.14 4.46 1.16

FLOWER MOUND, Texas, USA, Nov. 19, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, unveiled the Oculan Lighting Platform, an innovative lighting solution designed to provide consistent, high-quality illumination, allowing surgeons to focus on delivering the highest standard of care. In today's operating rooms, where precision and accuracy are critical, even the smallest challenges may impact surgical...Read more


IceCure Medical's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

November 19
Last Trade: 0.60 -0.0045 -0.75

PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialists PRECICE is exclusively using ProSense® to treat all 233 Luminal A and B patients >50 years of age with early-stage breast cancer, a wider population of patients than ICE3   Article published...Read more


enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

November 19
Last Trade: 3.30 -0.07 -2.08

Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment...Read more


EDAP TMS Announces Scientific Presentation at 2024 AAGL Global Congress Comparing Focal One HIFU Versus Surgery for the Treatment of Deep Infiltrating Endometriosis

November 19
Last Trade: 2.49 0.04 1.63

Treatment with robotic HIFU showed reduction in moderate and severe post-operative complications and reduced hospital stay compared to surgery LYON, France, November 19, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced a moderated scientific presentation of clinical data comparing Focal One HIFU versus surgery for the treatment of deep infiltrating endometriosis at the 2024 AAGL...Read more


Inspire Medical Systems to Present at Piper Sandler 36th Annual Healthcare Conference

November 19
Last Trade: 185.94 1.17 0.63

MINNEAPOLIS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Inspire is scheduled to present at...Read more


Medtronic reports second quarter fiscal 2025 financial results

November 19
Last Trade: 84.74 0.63 0.75

Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises:  TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, Nov. 19, 2024 /CNW/ -- Medtronic plc (NYSE: MDT) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024. Key Highlights Revenue of...Read more


Teleflex to Present at the 36th Annual Piper Sandler Healthcare Conference

November 19
Last Trade: 190.64 3.21 1.71

WAYNE, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 36th Annual Piper Sandler Healthcare Conference at The Lotte New York Palace, New York, NY, on Tuesday, December 3, 2024, at 9:30 a.m. (ET). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About...Read more


Spectral AI Raises Up to $5 Million Financing Strengthening Financial Position for FDA Pathway

November 19
Last Trade: 1.14 0.08 7.55

DALLAS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the successful completion of an approximate $5.0 million equity financing in an at-the-market transaction. The closing is to be completed in two tranches. Part of...Read more


GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

November 18
Last Trade: 16.38 1.29 8.55

MENLO PARK, Calif., Nov. 18, 2024  /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma...Read more


InfuSystem Appoints Ronald Hundzinski to the Board of Directors

November 18
Last Trade: 9.24 0.22 2.44

ROCHESTER HILLS, Mich. / Nov 18, 2024 / Business Wire / InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of Ronald Hundzinski, as an independent director to InfuSystem’s Board of Directors, effective November 12, 2024. Mr....Read more


Paragon 28 to Present at the 36th Annual Piper Sandler Healthcare Conference

November 18
Last Trade: 10.43 0.08 0.77

ENGLEWOOD, Colo. / Nov 18, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Chadi Chahine, CFO, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time. A live webcast,...Read more


New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches

November 18
Last Trade: 4.36 0.13 3.07

Furthering Nevro's body of evidence as an innovation leader in pain management, data highlights the company's posterior integrated transfixation cage system REDWOOD CITY, Calif., Nov. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in Medical Devices: Evidence and...Read more


Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

November 18
Last Trade: 1.00 -0.001 -0.10

NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024 at 1:30 p.m. ET. Live and...Read more


iRhythm Technologies Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring

November 18
Last Trade: 73.90 0.16 0.22

SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the results of five new studies presented at the American Heart Association’s 2024 Scientific Sessions in Chicago, IL. The findings underscore iRhythm’s commitment to advancing ambulatory cardiac monitoring services to improve patient outcomes, enhance healthcare resource utilization, and provide access to affordable care, including...Read more


Ekso Bionics to Showcase Its Device Technology in ‘AI for Good’ Webinar on Tuesday, November 19

November 18
Last Trade: 0.72 0.001 0.14

SAN RAFAEL, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Katherine Strausser, Principal Controls Engineer at Ekso Bionics, will be participating in an ‘AI for Good’ webinar. The webinar, entitled “AI-powered Exoskeletons Revolutionizing Rehabilitation and Mobility”, will take place on...Read more


Zimmer Biomet Announces CE Mark Certification for Persona® Revision Knee System

November 18
Last Trade: 108.40 -0.87 -0.80

WARSAW, Ind., and ZURICH, Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing surgeons with advanced tools for revision knee arthroplasty. "After the successful introduction of Persona...Read more


REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter

November 17
Last Trade: 8.96 0.02 0.22

This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer’s request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year...Read more


Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial

November 16
Last Trade: 91.50 1.33 1.47

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, Nov. 16, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device....Read more


Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

November 15
Last Trade: 2.98 -3.19 -51.70

SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor...Read more


Outset Medical to Present at the 2024 Stifel Healthcare Conference

November 15
Last Trade: 0.76 0.03 4.73

SAN JOSE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 2024 Stifel Healthcare conference on Tuesday, November 19, 2024, at 10:20 a.m. Eastern time. A live and archived webcast of the presentation will be available on...Read more


Boston Scientific Closes Acquisition of Axonics

November 15
Last Trade: 91.50 1.33 1.47

MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with...Read more


SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

November 15
Last Trade: 2.20 0.05 2.33

DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has begun shipping QUELIMMUNE™ to a third hospital customer. QUELIMMUNE is the Company’s Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute...Read more


Encision Reports Second Quarter Fiscal Year 2025 Results

November 15
Last Trade: 0.40 0.00 0.00

BOULDER, CO / ACCESSWIRE / November 15, 2024 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2025 second quarter that ended September 30, 2024. The Company posted quarterly product net revenue of $1.65 million and service net revenue of $101...Read more


Theralase Technologies Closes Non-Brokered Private Placement

November 15
Last Trade: 0.29 0.005 1.75

TORONTO, ON / ACCESSWIRE / November 15, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has...Read more


Tivic Health Systems Reports Third Quarter 2024 Financial Results and Provides Business Update

November 14
Last Trade: 0.24 -0.0069 -2.77

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m EDT FREMONT, Calif. / Nov 14, 2024 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and...Read more


Retractable Technologies Results for the Periods Ended September 30, 2024

November 14
Last Trade: 0.61 0.02 4.21

LITTLE ELM, Texas / Nov 14, 2024 / Business Wire / Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $10.3 million for the third quarter of 2024 and an operating loss of $5.1 million for the period, as compared to total net sales for the same period last year of $10.3 million and an operating loss of $936 thousand. For the first nine months of the year, net sales were $24.0 million and operating losses were...Read more


Movano Health Reports Q3 2024 Financial Results and Provides Business Update

November 14
Last Trade: 3.18 0.07 2.25

Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain...Read more


Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

November 14
Last Trade: 4.40 0.02 0.46

Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro,...Read more


Akoya Biosciences Reports Third Quarter 2024 Financial Results

November 14
Last Trade: 2.12 -0.04 -1.85

MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. “Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of...Read more


Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter

November 14
Last Trade: 8.96 0.02 0.22

Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Signed a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc....Read more


LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

November 14
Last Trade: 51.70 1.65 3.30

LONDON / Nov 14, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present a general business update during fireside chats at the three following healthcare conferences in New York in November and December: Stifel Healthcare Conference 2024 on Tuesday, November 19 from 11:30 a.m. - 12:00 p.m. Eastern Time, 6th Annual Wolfe...Read more


Stryker launches next generation of SurgiCount+ to help improve the standard of care in hospitals for sponge management and blood loss assessment

November 14
Last Trade: 390.14 4.46 1.16

PORTAGE, Mich., USA, Nov. 14, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its sponge management portfolio. Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit...Read more


Enrollment Complete in Tivic Health Systems Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

November 14
Last Trade: 0.24 -0.0069 -2.77

FREMONT, Calif. / Nov 14, 2024 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation (VNS) device. The study is being conducted by The Feinstein Institute of Bioelectronic Medicine. The objective of the...Read more


Hamilton Thorne Reports Revenue for the Quarter and Nine Months Ended September 30, 2024

November 14
Last Trade: 2.24 -0.01 -0.44

Revenue of $19.4 million and Adjusted EBITDA of $3.7 million for the quarter Beverly, Massachusetts and Toronto, Ontario--(Newsfile Corp. - November 14, 2024) - Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software, and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported unaudited condensed interim financial...Read more


TriSalus Life Sciences Reports Q3 2024 Financial Results and Provides Business Update

November 14
Last Trade: 4.43 0.36 8.85

Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system’s full access to the...Read more


Integer to Present at Piper Sandler Healthcare Conference on Dec. 3, 2024

November 14
Last Trade: 135.88 2.51 1.88

PLANO, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), will participate in the Piper Sandler 36th Annual Healthcare Conference, to be held Dec. 3 – 5 in New York City. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present Tuesday, Dec. 3, 2024, at 10:30 a.m. EST. The presentation will be...Read more


VentriPoint Diagnostics Announces Closing of Second and Final Tranche of Non-Brokered Private Placement Pursuant to Listed Issuer Financing Exemption

November 14
Last Trade: 0.13 -0.01 -7.14

Toronto, Ontario – TheNewswire - November 14, 2024 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) announces it has closed the second and final tranche of its non-brokered private placement offering, as described in its press releases of August 28, 2024, August 29, 2024, September 17, 2024, October 15, 2024, and October 18, 2024 pursuant to the listed issuer financing exemption under Part 5A of NI 45-105 -...Read more


Milestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO

November 14
Last Trade: 0.71 0.03 4.42

ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of the company on December 31, 2024. Upon his retirement, Mr. Haverhals will continue to serve as a director on the Board and will provide...Read more


PAVmed Provides Business Update and Third Quarter 2024 Financial Results

November 14
Last Trade: 1.00 -0.001 -0.10

Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The Ohio State's James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor Ongoing initiatives position PAVmed to preserve Nasdaq listing Conference call and webcast to be held today, November 14th...Read more


Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events

November 14
Last Trade: 2.20 0.05 2.33

WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. “The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the...Read more


Perimeter Medical Imaging AI Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 14
Last Trade: 0.62 -0.04 -6.06

Conference Call/Webcast Today at 5 pm ET TORONTO and DALLAS, Nov. 14, 2024 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today reported financial results for its third quarter ended September 30, 2024 and provided a corporate update. Business Highlights  The Company continues to gain positive commercial market...Read more


Milestone Scientific Achieves 22% Increase in Revenue for the Third Quarter of 2024

November 14
Last Trade: 0.71 0.03 4.42

Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in multiple U.S. states ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise...Read more


Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

November 14
Last Trade: 2.95 0.06 2.08

Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing...Read more


QHSLab Reports Record Q3 2024 Revenues, Reflecting Accelerated Expansion in Digital Health and Allergy Diagnostics

November 14
Last Trade: 0.09 0.00 0.00

Revenue Soars 62% Year-Over-Year in Q3 2024, with Gross Margin Expanding to 67.1% Integrated Service Program (ISP) Revenue Up 143% Year-to-Date, Marking Continued Demand for Digital Health Solutions Net Income of $49,765 for the Quarter Reflects Operational Efficiencies and Strategic Focus Strengthens Balance Sheet with Over $100,000 in Debt Repayments, Highlighting Commitment to Sustainability and Growth. Milestone Achievement:...Read more


ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

November 13
Last Trade: 11.09 0.13 1.19

Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using...Read more


NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially

November 13
Last Trade: 3.27 -0.03 -0.91

Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing Gross profit margin for the quarter was 43.6% compared to 28.2% in Q3 of 2023 and 28.5% in Q2 of 2024 LANGHORNE, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and...Read more


Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

November 13
Last Trade: 0.39 -0.0049 -1.26

Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer Trial Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical...Read more


Baxter to Present at Jefferies London Healthcare Conference

November 13
Last Trade: 32.99 0.36 1.10

DEERFIELD, Ill. / Nov 13, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 11:00 a.m. Greenwich Mean Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Monday, May 19,...Read more


Integra’s DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research

November 13
Last Trade: 23.00 0.07 0.31

PRINCETON, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the publication of a new economic study, “PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: An economic comparison across five European countries.”1 The purpose of this evaluation was to assess the budget-impact of switching patient treatment from...Read more


KORU Medical Systems Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-Digit Growth; Raises Full Year 2024 Guidance

November 13
Last Trade: 3.58 -0.07 -1.92

MAHWAH, N.J. / Nov 13, 2024 / Business Wire / KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2024, and raised full year 2024 revenue, gross margin, and year-end...Read more


HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

November 13
Last Trade: 2.62 -0.02 -0.76

Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025...Read more


Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission

November 13
Last Trade: 1.64 0.24 17.14

PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced strong initial...Read more


electroCore Announces Third Quarter 2024 Financial Results

November 13
Last Trade: 9.92 -0.02 -0.20

Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales  Company to host a conference call and webcast today, November 13, 2024 at 4:30 p.m. EST ROCKAWAY, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2024 financial...Read more


Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

November 13
Last Trade: 1.33 0.04 3.10

Regulatory approval to initiate first-in-human study with a miniature, ultra long-acting GLP-1 (exenatide) implant in obese or overweight individuals in Australia Miniature, ultra long-acting GLP-1 implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Announces $5M equity financing which secures solid financial position into late 2025,...Read more


Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results

November 13
Last Trade: 1.00 -0.001 -0.10

EsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue growth Conference call and webcast to be held today, November 13th at 8:30 AM EST NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer...Read more


Allurion Technologies Reports Third Quarter 2024 Financial Results and Provides Business Update

November 13
Last Trade: 0.51 0.05 11.62

NATICK, Mass. / Nov 13, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Recent Company Highlights Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled from France during the third quarter AI product...Read more


STRATA Skin Sciences Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

November 13
Last Trade: 3.10 0.01 0.32

HORSHAM, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended September 30, 2024 and provides a corporate update. Third Quarter 2024 Highlights Revenue in the third quarter of...Read more


Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

November 13
Last Trade: 0.69 0.04 5.58

PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate...Read more


Venus Concept Announces Third Quarter of Fiscal Year 2024 Financial Results

November 13
Last Trade: 0.29 -0.01 -4.29

TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2024. Summary of Financial Results & Recent Progress: Company continues to execute against Transformation Plan Cash used in operations for the first nine months of 2024 of $7.3 million, down...Read more


SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

November 13
Last Trade: 2.20 0.05 2.33

DENVER, Nov. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2024, and provides a business update. “We are delighted to report market demand and our first...Read more


Baxter to Present at Stifel 2024 Healthcare Conference

November 12
Last Trade: 32.99 0.36 1.10

DEERFIELD, Ill. / Nov 12, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 8:35 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Saturday, May 17, 2025. About...Read more


Electromed Announces Fiscal 2025 First Quarter Financial Results

November 12
Last Trade: 28.07 -1.14 -3.90

Electromed delivers eighth consecutive quarter of year-over-year revenue and profit growth, while continuing to invest in strategic growth initiatives NEW PRAGUE, Minn. / Nov 12, 2024 / Business Wire / Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2024 (“Q1 FY 2025”). Q1 FY 2025 Financial...Read more


Ceribell Reports Third Quarter 2024 Financial Results

November 12
Last Trade: 26.53 0.00 0.00

SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2024.   Third Quarter 2024 & Recent Highlights Reported total revenue of $17.2 million in the third quarter of 2024, a 48%...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Medical Device Gainers

 
CompanyChangeLast Trade
West Pharmaceutical 9.22 2.96 $320.88
Intuitive Surgical 8.80 1.62 $550.62
Semler Scientific 7.16 12.08 $66.43
Stryker 4.46 1.16 $390.14
Masimo 4.17 2.53 $169.12
STERIS 3.52 1.66 $215.77
Teleflex 3.21 1.71 $190.64
Becton Dickinson 3.06 1.38 $225.45
Repligen 2.86 2.06 $141.76
Bruker 2.85 5.34 $56.22
TransMedics 2.56 3.32 $79.76
Integer 2.51 1.88 $135.88
LeMaitre Vascular 2.43 2.35 $105.87
ResMed 2.05 0.85 $243.60
Bio-Rad Laboratories 1.89 0.58 $325.58

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB